HOOKIPA Pharma, Inc. (HOOK) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Spero Therapeutics, Inc.

Rani Therapeutics Holdings, Inc.

Shattuck Labs, Inc.

Aspira Women's Health, Inc.

HOOKIPA Pharma, Inc.

Solid Biosciences, Inc.

Nkarta, Inc.

Instil Bio, Inc.

CEL-SCI Corp.

Intensity Therapeutics, Inc.

OKYO Pharma Ltd.

Why is HOOKIPA Pharma, Inc. ?

The company has declared Negative results for the last 3 consecutive quarters

NET SALES(HY) At USD 8.8 MM has Grown at -76.78%
NET PROFIT(HY) At USD -17.08 MM has Grown at -403.98%
ROCE(HY) Lowest at -97.61%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -10.74%, its profits have fallen by -46.4%

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 13.68% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -10.74% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is HOOKIPA Pharma, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

HOOKIPA Pharma, Inc.

-11.57%

-1.23

69.95%

S&P 500

13.68%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-1.52%

EBIT Growth (5y)

-4.85%

EBIT to Interest (avg)

-67.68

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.18

Sales to Capital Employed (avg)

0.42

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

70.44%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.47

EV to EBIT

0.35

EV to EBITDA

0.36

EV to Capital Employed

3.82

EV to Sales

-1.39

PEG Ratio

Dividend Yield

ROCE (Latest)

1094.52%

ROE (Latest)

-176.14%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -111.16% (YoY

NET SALES(Q)

Highest at USD 6.79 MM

OPERATING PROFIT(Q)

Highest at USD -6.21 MM

OPERATING PROFIT MARGIN(Q)

Highest at -91.35 %

PRE-TAX PROFIT(Q)

Highest at USD -1.79 MM

NET PROFIT(Q)

Highest at USD -1.79 MM

EPS(Q)

Highest at USD -0.14

-19What is not working for the Company

NET SALES(HY)

At USD 8.8 MM has Grown at -76.78%

NET PROFIT(HY)

At USD -17.08 MM has Grown at -403.98%

ROCE(HY)

Lowest at -97.61%

CASH AND EQV(HY)

Lowest at USD 74.72 MM

Here's what is working for HOOKIPA Pharma, Inc.

Net Sales

At USD 6.79 MM has Grown at 190.66%

over average net sales of the previous four periods of USD 2.34 MM

MOJO Watch

Near term sales trend is extremely positive

Net Sales (USD MM)

Pre-Tax Profit

At USD -1.79 MM has Grown at 89.48%

over average net sales of the previous four periods of USD -16.97 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -1.79 MM has Grown at 89.46%

over average net sales of the previous four periods of USD -16.95 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (USD MM)

Net Sales

Highest at USD 6.79 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Operating Profit

Highest at USD -6.21 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -91.35 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at USD -1.79 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

Highest at USD -1.79 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD -0.14

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by -111.16% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for HOOKIPA Pharma, Inc.

Cash and Eqv

Lowest at USD 74.72 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents